-
-
13/03/2024 14/03/2024 America/Toronto Controlled Substances - Regulation, Litigation, and Enforcement Private: Controlled Substances – Regulation, Litigation, and Enforcement
March 13 – 14, 2024
Washington, DC
Please visit https://www.americanconference.com/controlled-substances/ for more information and updates. Washington, DC true DD/MM/YYYY 1440 use-title -
-
-
13/03/2024 14/03/2024 America/Toronto Controlled Substances - Regulation, Litigation, and Enforcement Private: Controlled Substances – Regulation, Litigation, and Enforcement
March 13 – 14, 2024
Washington, DC
Please visit https://www.americanconference.com/controlled-substances/ for more information and updates. Washington, DC true DD/MM/YYYY 1440 use-title -
Reevaluating Controlled Substances Prescribing via Telehealth and Appreciating the Impact of the Expiring PHE
Nathan A. Beaver
Partner
Foley & Lardner LLP
William Chang
Chief Legal Officer, Corporate Secretary
UpStream Healthcare
Scott B. Dahlquist
Opioid Coordinator, Consumer Protection Branch
U.S. Department of Justice
Julie Rapoport Schenker, Esq.
Senior Counsel, Business and Litigation | Office of the General Counsel
University of Maryland Medical System
- Considering the impact of the May 11, 2023, expiration of the PHE on controlled substances prescribing
- Will DEA create an official license for the prescribing of controlled substances via telehealth?
- Operating safely during the interim period of the expired PHE and the implementation of new DEA registrants for telehealth prescribers
- Detailing how the supply chain can prepare now for government’s plans to increase enforcement of telehealth prescribing
- Best practices for operating with differing state and federal requirements